Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Rani Therapeutics fourth quarter and full year 2023 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we would ask for a limit of one question and one follow-up, question per person. To ask a question at the time, please press star followed by 11 on your touch tone phone. As a reminder, this call is being recorded today, Wednesday, March 20th, 2024. I would now like to turn the conference call over to Kiki Patel at Gil Martin Group. Please go ahead. Thank you, operator. Joining us on the call today from Ronnie Therapeutics, our Chief Executive Officer, Talat Imran, VP of Clinical Development, Arvinder Dulla, and Chief Financial Officer, Svay Sanford. During this conference call, management will make forward-looking statements that are subject to risks, uncertainties, and assumptions, such as, but not limited to those discussed in the risk factors section of the company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These statements may include without limitation statements regarding product development and clinical trials, product potential, market sizes, platform progress, platform potential, certain business strategies, capital resources, financing plans, or operating performance. Actual results and the timing of events could differ materially from those projected in such forward-looking statemen...